These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 29389730)
1. Biomarkers and asthma management: analysis and potential applications. Richards LB; Neerincx AH; van Bragt JJMH; Sterk PJ; Bel EHD; Maitland-van der Zee AH Curr Opin Allergy Clin Immunol; 2018 Apr; 18(2):96-108. PubMed ID: 29389730 [TBL] [Abstract][Full Text] [Related]
2. Novel biomarkers for asthma stratification and personalized therapy. Bartminski G; Crossley M; Turcanu V Expert Rev Mol Diagn; 2015 Mar; 15(3):415-30. PubMed ID: 25479456 [TBL] [Abstract][Full Text] [Related]
3. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Arnold RJ; Massanari M; Lee TA; Brooks E Manag Care; 2018 Jul; 27(7):34-41. PubMed ID: 29989900 [TBL] [Abstract][Full Text] [Related]
4. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma. Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668 [TBL] [Abstract][Full Text] [Related]
5. Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma. Nagasaki T; Matsumoto H; Izuhara K; Allergol Int; 2017 Jul; 66(3):404-410. PubMed ID: 28256388 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Korevaar DA; Westerhof GA; Wang J; Cohen JF; Spijker R; Sterk PJ; Bel EH; Bossuyt PM Lancet Respir Med; 2015 Apr; 3(4):290-300. PubMed ID: 25801413 [TBL] [Abstract][Full Text] [Related]
7. Can biomarkers help us hit targets in difficult-to-treat asthma? Fricker M; Heaney LG; Upham JW Respirology; 2017 Apr; 22(3):430-442. PubMed ID: 28248008 [TBL] [Abstract][Full Text] [Related]
8. "T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Pavlidis S; Takahashi K; Ng Kee Kwong F; Xie J; Hoda U; Sun K; Elyasigomari V; Agapow P; Loza M; Baribaud F; Chanez P; Fowler SJ; Shaw DE; Fleming LJ; Howarth PH; Sousa AR; Corfield J; Auffray C; De Meulder B; Knowles R; Sterk PJ; Guo Y; Adcock IM; Djukanovic R; Fan Chung K; Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30578390 [TBL] [Abstract][Full Text] [Related]
9. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. van der Schee MP; Palmay R; Cowan JO; Taylor DR Clin Exp Allergy; 2013 Nov; 43(11):1217-25. PubMed ID: 24152154 [TBL] [Abstract][Full Text] [Related]
10. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. Jia G; Erickson RW; Choy DF; Mosesova S; Wu LC; Solberg OD; Shikotra A; Carter R; Audusseau S; Hamid Q; Bradding P; Fahy JV; Woodruff PG; Harris JM; Arron JR; J Allergy Clin Immunol; 2012 Sep; 130(3):647-654.e10. PubMed ID: 22857879 [TBL] [Abstract][Full Text] [Related]
12. Elevated fractional exhaled nitric oxide (FeNO) is a clinical indicator of uncontrolled asthma in children receiving inhaled corticosteroids. Yin SS; Liu H; Gao X Int J Clin Pharmacol Ther; 2017 Jan; 55(1):66-77. PubMed ID: 27443657 [TBL] [Abstract][Full Text] [Related]
13. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469 [TBL] [Abstract][Full Text] [Related]
14. Relationship between total serum immunoglobulin E levels, fractional exhaled breath nitric oxide levels and absolute blood eosinophil counts in atopic and non-atopic asthma: a controlled comparative study. Shrestha SK; Drews A; Sharma L; Pant S; Shrestha S; Neopane A J Breath Res; 2018 Feb; 12(2):026009. PubMed ID: 29068321 [TBL] [Abstract][Full Text] [Related]
16. Immunological biomarkers in severe asthma. Narendra D; Blixt J; Hanania NA Semin Immunol; 2019 Dec; 46():101332. PubMed ID: 31735516 [TBL] [Abstract][Full Text] [Related]
17. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study. Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296 [TBL] [Abstract][Full Text] [Related]
18. The value of FeNO measurement in asthma management: the motion for Yes, it's NO--or, the wrong end of the Stick! Bush A; Eber E Paediatr Respir Rev; 2008 Jun; 9(2):127-31. PubMed ID: 18513673 [TBL] [Abstract][Full Text] [Related]
19. Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. Couillard S; Shrimanker R; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord ID; Hinks TSC Am J Respir Crit Care Med; 2021 Sep; 204(6):731-734. PubMed ID: 34129808 [No Abstract] [Full Text] [Related]
20. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]